321 related articles for article (PubMed ID: 33876389)
1. Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.
Reeves BN; Beckman JD
Curr Hematol Malig Rep; 2021 Jun; 16(3):304-313. PubMed ID: 33876389
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.
Haage TR; Charakopoulos E; Bhuria V; Baldauf CK; Korthals M; Handschuh J; Müller P; Li J; Harit K; Nishanth G; Frey S; Böttcher M; Fischer KD; Dudeck J; Dudeck A; Lipka DB; Schraven B; Green AR; Müller AJ; Mougiakakos D; Fischer T
J Hematol Oncol; 2024 Jun; 17(1):43. PubMed ID: 38853260
[TBL] [Abstract][Full Text] [Related]
3. Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features.
Guadall A; Lesteven E; Letort G; Awan Toor S; Delord M; Pognant D; Brusson M; Verger E; Maslah N; Giraudier S; Larghero J; Vanneaux V; Chomienne C; El Nemer W; Cassinat B; Kiladjian JJ
Thromb Haemost; 2018 Sep; 118(9):1586-1599. PubMed ID: 30103245
[TBL] [Abstract][Full Text] [Related]
4. Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
Bhuria V; Baldauf CK; Schraven B; Fischer T
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328626
[TBL] [Abstract][Full Text] [Related]
5. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin Oyarzún CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
6. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Mahjoub S; Baccouche H; Sahnoun M; Kaabi H; Manai Z; Slama H; Ben Romdhane N
Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
[TBL] [Abstract][Full Text] [Related]
7. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Hexner EO
Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
[TBL] [Abstract][Full Text] [Related]
9. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Wolach O; Sellar RS; Martinod K; Cherpokova D; McConkey M; Chappell RJ; Silver AJ; Adams D; Castellano CA; Schneider RK; Padera RF; DeAngelo DJ; Wadleigh M; Steensma DP; Galinsky I; Stone RM; Genovese G; McCarroll SA; Iliadou B; Hultman C; Neuberg D; Mullally A; Wagner DD; Ebert BL
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643232
[TBL] [Abstract][Full Text] [Related]
10. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms.
Teofili L; Martini M; Iachininoto MG; Capodimonti S; Nuzzolo ER; Torti L; Cenci T; Larocca LM; Leone G
Blood; 2011 Mar; 117(9):2700-7. PubMed ID: 21212285
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
12. JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
Irino T; Uemura M; Yamane H; Umemura S; Utsumi T; Kakazu N; Shirakawa T; Ito M; Suzuki T; Kinoshita K
PLoS One; 2011; 6(7):e22148. PubMed ID: 21789226
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial cell expression of JAK2
Guy A; Gourdou-Latyszenok V; Le Lay N; Peghaire C; Kilani B; Dias JV; Duplaa C; Renault MA; Denis C; Villeval JL; Boulaftali Y; Jandrot-Perrus M; Couffinhal T; James C
Haematologica; 2019 Jan; 104(1):70-81. PubMed ID: 30171023
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
Baccouche H; Ben Jemaa M; Chakroun A; Chadi S; Mahjoub S; Sfar I; Gorgi Y; Ben Romdhane N
Int J Lab Hematol; 2017 Oct; 39(5):502-507. PubMed ID: 28497580
[TBL] [Abstract][Full Text] [Related]
15. Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.
Kissova J; Bulikova A; Ovesna P; Bourkova L; Penka M
Int J Hematol; 2014 Nov; 100(5):429-36. PubMed ID: 25227185
[TBL] [Abstract][Full Text] [Related]
16. Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms.
Guy A; Garcia G; Gourdou-Latyszenok V; Wolff-Trombini L; Josserand L; Kimmerlin Q; Favre S; Kilani B; Marty C; Boulaftali Y; Labrouche-Colomer S; Mansier O; James C
J Thromb Haemost; 2024 Jan; 22(1):172-187. PubMed ID: 37678548
[TBL] [Abstract][Full Text] [Related]
17. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
18. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
[TBL] [Abstract][Full Text] [Related]
19. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
20. Thrombotic and bleeding complications in classical myeloproliferative neoplasms.
McMahon B; Stein BL
Semin Thromb Hemost; 2013 Feb; 39(1):101-11. PubMed ID: 23264112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
